Results for tag: "NRF2 Pathway Activator"

The NRF2 Pathway Activator market within the context of Central Nervous System Drugs is a rapidly growing field of research. It is focused on the development of drugs that can activate the NRF2 pathway, a key regulator of the body's response to oxidative stress. These drugs have the potential to treat a variety of neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. The NRF2 Pathway Activator market is driven by the increasing prevalence of neurological disorders, as well as the need for more effective treatments. The development of these drugs is also being driven by advances in technology, such as the use of artificial intelligence and machine learning to identify potential drug targets. Several companies are involved in the NRF2 Pathway Activator market, including AbbVie, AstraZeneca, Biogen, GlaxoSmithKline, Merck, Novartis, and Pfizer. These companies are actively researching and developing drugs that can activate the NRF2 pathway, with the aim of providing more effective treatments for neurological disorders. Show Less Read more